Skip to Main Content

Buried deep within the Inflation Reduction Act’s drug-price negotiation provisions is language that could open the way to a new era of biomedical breakthroughs and smarter health spending.

This language does something Medicare hasn’t tried before: It ties payment for treatments to how well they work. Doing so used to be illegal. But it will now be required for some drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment